Setmelanotide (Imcivree)

FDA-approved product existsMelanocortin Receptor AgonistWeight & metabolic

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Setmelanotide (Imcivree)?

FDA-approved setmelanotide is marketed as Imcivree for chronic weight management in patients with obesity caused by specific rare genetic conditions covered by the label.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelIMCIVREE prescribing information for labeled genetic and syndromic obesity indications
PopulationAdults and pediatric patients covered by the approved IMCIVREE indications
DoseStarting and titration doses depend on age, indication, weight, tolerability, and kidney function. For adults and patients 12 years and older with BBS or POMC, PCSK1, or LEPR deficiency, the label starts at 2 mg once daily for 2 weeks and lists 3 mg once daily as maintenance if tolerated.
RouteSubcutaneous injection in the abdomen, thigh, or arm
FrequencyOnce daily at the beginning of the day
DurationLong-term use within the approved indication, with label-defined response assessment
PreparationReady-to-use 10 mg/mL solution in a 1 mL multiple-dose vial; no reconstitution.
Source: Dosage and Administration sections 2.1-2.6; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.